Targeting protein-protein interactions to rescue Δf508-cftr: A novel corrector approach to treat cystic fibrosis

EMBO Molecular Medicine

Volumn 5, Issue 10, 2013, Pages 1462-1464

  Devesa, Isabel ^a   Fernández Ballester, Gregorio ^a   Ferrer Montiel, Antonio ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Drug discovery; Ion channel; Lung disease; Proteostasis; Therapy

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PHENYLALANINE;

ARTICLE; CELIAC DISEASE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CHANNEL GATING; CODON; CYSTIC FIBROSIS; ENDOPLASMIC RETICULUM; GENITAL SYSTEM; HUMAN; LUNG FUNCTION; MISSENSE MUTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; QUALITY CONTROL; QUALITY OF LIFE; RESPIRATORY SYSTEM; SWEAT GLAND;

DRUG DISCOVERY; ION CHANNEL; LUNG DISEASE; PROTEOSTASIS; THERAPY;

ANIMALS; BRONCHI; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; SMALL MOLECULE LIBRARIES;

EID: 84884912798     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201303301     Document Type: Article

References (10)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003
2. Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56: 344-399
3. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12-18
4. Hanrahan JW, Sampson HM, Thomas DY (2013) Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci 34: 119-125
5. Kreindler JL (2010) Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther 125: 219-229
6. Lukacs GL, Verkman AS (2012) CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med 18: 81-91
7. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073
8. Rowe SM, Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 3, a009761
9. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, et al (2011) Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38: 59-69
10. Odolczyk N, Fritsch J, Norez C, Servel N, Faria da Cunha M, Bitam S, Kupniewska A, Wiszniewski L, Colas J, Tarnowski K et al (2013) Discovery of novel ΔF508-CFTR correctors by targeting the specific conformation of a nucleotide binding domain. EMBO Mol Med 5: 1484-1501